Impact of 2016 WHO diagnosis of early and overt primary myelofibrosis on presentation and outcome of 232 patients treated with ruxolitinib

Francesca Palandri, Giuseppe A. Palumbo, Elisabetta Abruzzese, Alessandra Iurlo, Nicola Polverelli, Elena Elli, Massimiliano Bonifacio, Micaela Bergamaschi, Bruno Martino, Mario Tiribelli, Giulia Benevolo, Alessia Tieghi, Nicola Sgherza, Alessandro Isidori, Gianni Binotto, Monica Crugnola, Florian Heidel, Francesco Cavazzini, Costanza Bosi, Giuseppe AuteriDaniele Cattaneo, Robin Foà, Roberto M. Lemoli, Antonio Cuneo, Mauro Krampera, Daniela Bartoletti, Michele Cavo, Nicola Vianelli, Massimo Breccia, Roberto Latagliata

Research output: Contribution to journalArticle

Abstract

The 2016 WHO criteria identified early primary myelofibrosis (PMF) as an individual entity with milder clinical features and better outcome compared with overt PMF. Here, we compared early and overt PMF patients treated with ruxolitinib in terms of baseline clinical/laboratory characteristics, response, and toxicity to treatment. We observed that early-PMF patients achieve better and more stable spleen and symptoms responses, with significantly lower rates of hematological toxicities. No differences in overall and leukemia-free survival were detected between the two cohorts. The application of 2016 WHO criteria is crucial to identify those PMF patients who deserve a stricter monitoring during treatment.

Original languageEnglish
Pages (from-to)418-423
Number of pages6
JournalHematological Oncology
Volume37
Issue number4
DOIs
Publication statusPublished - Oct 1 2019

Fingerprint

Primary Myelofibrosis
Leukemia
Spleen
INCB018424
Survival
Therapeutics

Keywords

  • EARLY PMF
  • MYELOFIBROSIS
  • OVERT PMF
  • RUXOLITINIB

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Impact of 2016 WHO diagnosis of early and overt primary myelofibrosis on presentation and outcome of 232 patients treated with ruxolitinib. / Palandri, Francesca; Palumbo, Giuseppe A.; Abruzzese, Elisabetta; Iurlo, Alessandra; Polverelli, Nicola; Elli, Elena; Bonifacio, Massimiliano; Bergamaschi, Micaela; Martino, Bruno; Tiribelli, Mario; Benevolo, Giulia; Tieghi, Alessia; Sgherza, Nicola; Isidori, Alessandro; Binotto, Gianni; Crugnola, Monica; Heidel, Florian; Cavazzini, Francesco; Bosi, Costanza; Auteri, Giuseppe; Cattaneo, Daniele; Foà, Robin; Lemoli, Roberto M.; Cuneo, Antonio; Krampera, Mauro; Bartoletti, Daniela; Cavo, Michele; Vianelli, Nicola; Breccia, Massimo; Latagliata, Roberto.

In: Hematological Oncology, Vol. 37, No. 4, 01.10.2019, p. 418-423.

Research output: Contribution to journalArticle

Palandri, F, Palumbo, GA, Abruzzese, E, Iurlo, A, Polverelli, N, Elli, E, Bonifacio, M, Bergamaschi, M, Martino, B, Tiribelli, M, Benevolo, G, Tieghi, A, Sgherza, N, Isidori, A, Binotto, G, Crugnola, M, Heidel, F, Cavazzini, F, Bosi, C, Auteri, G, Cattaneo, D, Foà, R, Lemoli, RM, Cuneo, A, Krampera, M, Bartoletti, D, Cavo, M, Vianelli, N, Breccia, M & Latagliata, R 2019, 'Impact of 2016 WHO diagnosis of early and overt primary myelofibrosis on presentation and outcome of 232 patients treated with ruxolitinib', Hematological Oncology, vol. 37, no. 4, pp. 418-423. https://doi.org/10.1002/hon.2619
Palandri, Francesca ; Palumbo, Giuseppe A. ; Abruzzese, Elisabetta ; Iurlo, Alessandra ; Polverelli, Nicola ; Elli, Elena ; Bonifacio, Massimiliano ; Bergamaschi, Micaela ; Martino, Bruno ; Tiribelli, Mario ; Benevolo, Giulia ; Tieghi, Alessia ; Sgherza, Nicola ; Isidori, Alessandro ; Binotto, Gianni ; Crugnola, Monica ; Heidel, Florian ; Cavazzini, Francesco ; Bosi, Costanza ; Auteri, Giuseppe ; Cattaneo, Daniele ; Foà, Robin ; Lemoli, Roberto M. ; Cuneo, Antonio ; Krampera, Mauro ; Bartoletti, Daniela ; Cavo, Michele ; Vianelli, Nicola ; Breccia, Massimo ; Latagliata, Roberto. / Impact of 2016 WHO diagnosis of early and overt primary myelofibrosis on presentation and outcome of 232 patients treated with ruxolitinib. In: Hematological Oncology. 2019 ; Vol. 37, No. 4. pp. 418-423.
@article{9381b41fc4b248f08941ae1dc91fa30b,
title = "Impact of 2016 WHO diagnosis of early and overt primary myelofibrosis on presentation and outcome of 232 patients treated with ruxolitinib",
abstract = "The 2016 WHO criteria identified early primary myelofibrosis (PMF) as an individual entity with milder clinical features and better outcome compared with overt PMF. Here, we compared early and overt PMF patients treated with ruxolitinib in terms of baseline clinical/laboratory characteristics, response, and toxicity to treatment. We observed that early-PMF patients achieve better and more stable spleen and symptoms responses, with significantly lower rates of hematological toxicities. No differences in overall and leukemia-free survival were detected between the two cohorts. The application of 2016 WHO criteria is crucial to identify those PMF patients who deserve a stricter monitoring during treatment.",
keywords = "EARLY PMF, MYELOFIBROSIS, OVERT PMF, RUXOLITINIB",
author = "Francesca Palandri and Palumbo, {Giuseppe A.} and Elisabetta Abruzzese and Alessandra Iurlo and Nicola Polverelli and Elena Elli and Massimiliano Bonifacio and Micaela Bergamaschi and Bruno Martino and Mario Tiribelli and Giulia Benevolo and Alessia Tieghi and Nicola Sgherza and Alessandro Isidori and Gianni Binotto and Monica Crugnola and Florian Heidel and Francesco Cavazzini and Costanza Bosi and Giuseppe Auteri and Daniele Cattaneo and Robin Fo{\`a} and Lemoli, {Roberto M.} and Antonio Cuneo and Mauro Krampera and Daniela Bartoletti and Michele Cavo and Nicola Vianelli and Massimo Breccia and Roberto Latagliata",
year = "2019",
month = "10",
day = "1",
doi = "10.1002/hon.2619",
language = "English",
volume = "37",
pages = "418--423",
journal = "Hematological Oncology",
issn = "0278-0232",
publisher = "wiley",
number = "4",

}

TY - JOUR

T1 - Impact of 2016 WHO diagnosis of early and overt primary myelofibrosis on presentation and outcome of 232 patients treated with ruxolitinib

AU - Palandri, Francesca

AU - Palumbo, Giuseppe A.

AU - Abruzzese, Elisabetta

AU - Iurlo, Alessandra

AU - Polverelli, Nicola

AU - Elli, Elena

AU - Bonifacio, Massimiliano

AU - Bergamaschi, Micaela

AU - Martino, Bruno

AU - Tiribelli, Mario

AU - Benevolo, Giulia

AU - Tieghi, Alessia

AU - Sgherza, Nicola

AU - Isidori, Alessandro

AU - Binotto, Gianni

AU - Crugnola, Monica

AU - Heidel, Florian

AU - Cavazzini, Francesco

AU - Bosi, Costanza

AU - Auteri, Giuseppe

AU - Cattaneo, Daniele

AU - Foà, Robin

AU - Lemoli, Roberto M.

AU - Cuneo, Antonio

AU - Krampera, Mauro

AU - Bartoletti, Daniela

AU - Cavo, Michele

AU - Vianelli, Nicola

AU - Breccia, Massimo

AU - Latagliata, Roberto

PY - 2019/10/1

Y1 - 2019/10/1

N2 - The 2016 WHO criteria identified early primary myelofibrosis (PMF) as an individual entity with milder clinical features and better outcome compared with overt PMF. Here, we compared early and overt PMF patients treated with ruxolitinib in terms of baseline clinical/laboratory characteristics, response, and toxicity to treatment. We observed that early-PMF patients achieve better and more stable spleen and symptoms responses, with significantly lower rates of hematological toxicities. No differences in overall and leukemia-free survival were detected between the two cohorts. The application of 2016 WHO criteria is crucial to identify those PMF patients who deserve a stricter monitoring during treatment.

AB - The 2016 WHO criteria identified early primary myelofibrosis (PMF) as an individual entity with milder clinical features and better outcome compared with overt PMF. Here, we compared early and overt PMF patients treated with ruxolitinib in terms of baseline clinical/laboratory characteristics, response, and toxicity to treatment. We observed that early-PMF patients achieve better and more stable spleen and symptoms responses, with significantly lower rates of hematological toxicities. No differences in overall and leukemia-free survival were detected between the two cohorts. The application of 2016 WHO criteria is crucial to identify those PMF patients who deserve a stricter monitoring during treatment.

KW - EARLY PMF

KW - MYELOFIBROSIS

KW - OVERT PMF

KW - RUXOLITINIB

UR - http://www.scopus.com/inward/record.url?scp=85067388782&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85067388782&partnerID=8YFLogxK

U2 - 10.1002/hon.2619

DO - 10.1002/hon.2619

M3 - Article

C2 - 30985017

AN - SCOPUS:85067388782

VL - 37

SP - 418

EP - 423

JO - Hematological Oncology

JF - Hematological Oncology

SN - 0278-0232

IS - 4

ER -